promise BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management
- Coordinator
- Time Is Brain SL, Spain
- Runs
- 1 May 2023 to 30 April 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €5.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190126352
What the project is doing
In the project's own words, from its summary on CORDIS.
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20 is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients brain viability, thereby predicting who will benefit from EVT.
Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20 will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Time Is Brain SL | Badalona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI